References
- [1]. T.W. Geisbert, P.B. Jahrling, Differentiation of filoviruses by electron microscopy, Virus Research 39 (1995) 129-150.10.1016/0168-1702(95)00080-1
- [2]. E. Picazo, F. Giordanetto, Small molecule inhibitors of Ebola virus infection, Drug Discovery Today 20 (2015) 277–286.10.1016/j.drudis.2014.12.01025532798
- [3]. World Health Organization (WHO). Ebola Situation Report March 30 (2016). https://www.who.int/csr/disease/ebola/en/
- [4]. J.J. Suschak, C.S. Schmaljohn Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates human, Vaccines and Immunotherapeutics 15 (2019) 2359-2377.
- [5]. S.A. Moghadam, Z. Abdollahi, S.R. Fakour, A. A. Moghaddam, F. Kiany, N. Damani, The Relationship Between Periodontal Disease and Public Health: A Population-Based Study, Global Journal of Health Science 8 (2015) 110-115. DOI: 10.5539/gjhs.v8n7p11010.5539/gjhs.v8n7p110496563826925886
- [6]. S. Baize, D. Pannetier, L. Oestereich, T. Rieger, L. Koivogui, N. Magassouba, B. Soropogui, M. S. Sow, S. Keïta,, H. De Clerck, A. Tiffany, G. Dominguez, M. Loua, A. Traoré, M. Kolié, E. R. Malano, E. Heleze,, A. Bocquin, S. Mély, H. Raoul, V. Caro, D. Cadar, M. Gabriel, M. Pahlmann, D. Tappe, J. Schmidt-Chanasit, B. Impouma, A. K. Diallo, P. Formenty, M. V. Herp, S. Günther, Emergence of Zaire Ebola virus disease in Guinea, New England Journal of Medivine 371 (2014) 1418-1425. DOI: 10.1056/NEJMoa140450510.1056/NEJMoa140450524738640
- [7]. R.K Singh, K. Dhama, Y.S. Malik, M. Andavar Ramakrishnan, K. Karthik, R. Khandia, R. Tiwari, A. Munjal, M. Saminathan, S. Sachan, P.A. Desingu, J.J. Kattoor, H.M.N. Iqbal, S.K. Joshi. Ebola virus – epidemiology, diagnosis, and control: threat to humans, lessons learnt, and preparedness plans – an update on its 40 year’s journey, Veterinary Quarterly 37 (2017) 98-135.
- [8]. F. Chiappelli, A. Bakhordarian, A.D. Thames, A.M. Du, A.L. Jan, M. Nahcivan, M.T. Nguyen, N. Sama, E. Manfrini, F. Piva, R.M. Rocha, C.A. Maida, Ebola: translational science considerations, Journal of Translational Medicine 13 (2015) 11-15.
- [9]. N.J. Beeching, M. Fenech, C.F. Houlihan, Critical Review: Ebola virus disease, British Medical Journal 349 (2014) g7348. DOI: 10.1136/bmj.g734810.1136/bmj.g7348470772025497512
- [10]. H. Ogawa, H. Miyamoto, E. Nakayama, R. Yoshida, I. Nakamura, H. Sawa, A. Ishii, Y. Thomas, E. Nakagawa, K. Matsuno, M. Kajihara, J. Maruyama, N. Nao, M. Muramatsu, M. Kuroda, E. Simulundu, K. Changula, B. Hang’ombe, B. Namangala, A. Nambota J. Katampi, M. Igarashi, K. Ito, H. Feldmann, C. Sugimoto, L. Moonga, A. Mweene, A. Takada, Seroepidemiological prevalence of multiple species of filoviruses in fruit bats (Eidolon helvum) migrating in Africa, Journal of Infectious Diseases 212 (2015) S101-S108.10.1093/infdis/jiv06325786916
- [11]. T. Ikegami, Molecular biology and genetic diversity of Rift Valley fever virus, Antiviral Research 95 (2012) 293-310.10.1016/j.antiviral.2012.06.001358693722710362
- [12]. O. Oluwagbemi, O. Awe, A comparative computational genomics of Ebola virus disease strains: Insilico insight for Ebola control, Informatics in Medicine Unlocked 12 (2018) 106– 119.
- [13]. M. Balmith, E.S. Soliman, Potential Ebola drug targets – filling the gap: a critical step forward towards the design and discovery of potential drugs, Journal Biologia 72 (2017) 1-13.
- [14]. M. Balmith, M. Faya, M.E. S. Soliman, Ebola virus: A gap in drug design and discovery - experimental and computational perspective, Chemical Biology and Drug Design 89 (2017) 297–308.
- [15]. B. Hartlieb, T. Muziol, W. Weissenhorn, S. Becker, Crystal structure of the C-terminal domain of Ebola virus VP30 reveals a role in transcription and nucleocapsid association, Proceeding of National Academy of Science, USA 104 (2007) 624-629.10.1073/pnas.0606730104211139917202263
- [16]. Y. Guo, S.S. Dong, P. Yang, G.B. Li, B.C. Liu, C. Yang, Z.H. Rao, Crystal structure of Ebola virus nucleoprotein core domain at 1.8A resolution, Protein Cell 6 (2015) 351-362.10.1007/s13238-015-0163-3441767525910597
- [17]. R.N. Kirchdoerfer, C.L. Moyer, D.M. Abelson, E.O. Saphire, Ebola virus VP30 CTD bound to 8-nucleoprotein PLoS Pathog 12 (2016) e1005937.10.1371/journal.ppat.1005937506870727755595
- [18]. Spartan user’s guide, Wave function, Inc, Irvine, CA 92612 USA
- [19]. W.J. Hehre, L. Radom, P.V.R. Schleyer, J.A. Pope, Ab initio molecular Orbital Theory, Wiley, New York, 1988.
- [20]. A.D. Becke, Density-functional thermochemistry. III. The role of exact exchange, Journal Chemical Physics 98 (1993) 5648. DOI: 10.1063/1.46491310.1063/1.464913
- [21]. C. Lee, W. Yang, R.G. Parr, Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density, Physical Review B 37 (1988) 785-789. DOI: 10.1103/physrevb.37.78510.1103/PhysRevB.37.785
- [22]. Spartan’14 Wavefunction, Inc. Irvine, CA, 2014
- [23]. M.N. Wass, L.A. Kelley, M.J.E. Sternberg, 3DLigandSite: predicting ligand-binding sites using similar structures, Nucleic Acids Research 38 (2010) W469–W473.10.1093/nar/gkq406289616420513649
- [24]. O. Trott, A.J. Olson, AutoDockVina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading, Journal of Computational Chemistry 31 (2010) 455–461.
- [25]. A.K Oyebamiji, E.K. Oladipo, T.M. Olotu, H.E. Awoyelu, E. Adamolekun, B. Semire, In-vitro Investigation on Selected compounds in Annona Muricata Seed: A Potential SARS-CoV nsp12 Polymerase Inhibitors down Regulating 2019-nCoV, International Journal of Traditional Natural Medicine 10 (2020) 13-23.
- [26]. A.K. Oyebamiji, G.F. Tolufashe, B. Semire, Inhibition study on anti-type 3 of 3α-hydroxysteroid dehydrogenase activity against 1,2,3-triazolo[4,5-D]pyrimidine derivatives: Molecular modelling approach, Scientific African 8 (2020) e00444.
- [27]. A.K. Oyebamiji, O.A Fadare, B. Semire, Hybrid-based drug design of 1,2,3-triazolepyrimidine-hybrid derivatives: Efficient inhibiting agents of mesenchymal–epithelial transition factor reducing gastric cancer cell growth, Journal of Chemical Research 44 (2020) 277-280. DOI: 10.1177/174751981989835410.1177/1747519819898354
- [28]. R.O. Oyewole, A.K. Oyebamiji, B. Semire, Theoretical Calculations of Molecular Descriptors for Anticancer Activities of 1,2,3-Triazolepyrimidine derivatives against Gastric cancer cell (MGC-803): DFT, QSAR and Docking Approaches, Heliyon 6 (2020) e03926. DOI: 10.1016/j.heliyon.2020.e0392610.1016/j.heliyon.2020.e03926724314132462084
- [29]. A.E. Adegbola, O.S. Fadahunsi, A.A. Ayodeji Z. Abijo, T.A. Balogun, T.S. Aderibigbe, B. Semire, P.I. Adegbola, Computational prediction of nimbanal as potential antagonist of respiratory syndrome coronavirus, Informatics in Medicine Unlocked 24 (2021) 100617. DOI: 10.1016/j.imu.2021.10061710.1016/j.imu.2021.100617816173634075339
- [30]. P.I. Adegbola, O.S. Fadahunsi, A.E. Adegbola, B. Semire, In silico studies of potency and safety assessment of selected trial drugs for the treatment of COVID-19, In Silico Pharmacology 9 (2001) 45. DOI: 10.1007/s40203-021-00105-x10.1007/s40203-021-00105-x829503034312587
- [31]. P.I. Adegbola, B. Semire, O.S. Fadahunsi A.E. Adegoke, Molecular docking and ADMET studies of Allium cepa, Azadirachta indica and Xylopia aethiopica isolates as potential anti-viral drugs for Covid-19, Virus Disease 32 (2021) 85-97.10.1007/s13337-021-00682-7803601333869672
- [32]. A.K. Oyebamiji, S.A. Akintelu, O.P. Amao, M.O. Kaka, A.E. Morakinyo, F.A. Amao, B. Semire, Dataset on theoretical bio-evaluation of 1,2,4-thiadiazole-1,2,4-triazole Analogues against epidermal growth factor receptor kinase down regulating human lung cancer. Data in Brief. 37 (2021) 107234. DOI: 10.1016/j.dib.2021.10723410.1016/j.dib.2021.107234822056134195309
- [33]. M.A.F. Nasution, E.P. Toepak, A.H. Alkaff, U.S. Tambunan, Flexible docking-based molecular dynamics simulation of natural product compounds and Ebola virus Nucleocapsid (EBOV NP): a computational approach to discover new drug for combating Ebola, BMC Bioinformatics 19 (2018) 419. DOI: 10.1186/s12859-018-2387-810.1186/s12859-018-2387-8624569230453886
- [34]. Y. Antonius, J. Ongko, J. Sukweenadhi, S.E. Dwi Putra, Identification of potential Ebola virus nucleoprotein (EBOV NP) inhibitor derivate from various traditional medicinal plants in Indonesia: in silico study, Media Pharmaceutica Indonesiana 3 (2021) 217-226.
- [35]. R.N. Kirchdoerfer, C.L. Moyer, D.M. Abelson, E.O. Saphire, The Ebola Virus VP30-NP Interaction Is a Regulator of Viral RNA Synthesis. PLoS Pathog 12 (2016) e1005937. DOI: 10.1371/journal.ppat.100593710.1371/journal.ppat.1005937506870727755595
- [36]. F. Darvas, G. Keseru, A. Papp, G. Dorman, L. Urge, P. Krajcsi, In Silico and Ex silico ADME approaches for drug discovery, Topics in Medicinal Chemistry 2 (2002) 1287–304.10.2174/156802602339284112470281
- [37]. H. Wen, H. Jung, X. Li, Drug delivery approaches in addressing clinical pharmacology-related issues: Opportunities and challenges, AAPS Journal 17 (2015) 1327–1340.
- [38]. C.A. Lipinski, Lead- and drug-like compounds: the rule-of-five revolution, Drug Discovery Today: Technologies 1 (2004) 337-341. DOI: 10.1016/j.ddtec.2004.11.00710.1016/j.ddtec.2004.11.00724981612
- [39]. A. Daina, V. Zoete, ABOILED-Egg to predict gastrointestinal absorption and brain penetration of small molecules, ChemMedChem 11 (2016) 1117– 1121.10.1002/cmdc.201600182508960427218427
- [40]. S.A. Attique, M. Hassan, M. Usman, R.M. Atif, S. Mahboob, K.A. Al-Ghanim, M. Bilal, M.Z. Nawaz, A molecular docking approach to evaluate the pharmacological properties of natural and synthetic treatment candidates for use against hypertension, International Journal of Environmental Research and Public Health 16 (2019) 923. DOI: 10.3390/ijerph1606092310.3390/ijerph16060923646610230875817
- [41]. D.E.V. Pires, T.L. Blundell, D.B. Ascher, pkCSM: predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures, Journal of Medicinal Chemistry 58 (2015) 4066– 4072.
- [42]. M.J. Waring, J. Arrowsmith, A.R. Leach, P.D. Leeson, S. Mandrell, R.M. Owen, An analysis of the attrition of drug candidates from four major pharmaceutical companies, Natural Review of Drug Discovery 14 (2015) 475–486.10.1038/nrd460926091267
- [43]. D.A. Flockhart, Drug Interactions: cytochrome P450 Drug Interaction Table. Indiana University School of Medicine’/clinpharm/ddis/clinical-table/’’. 2007; Accessed August 12th 2018